fbpx

molecules of the month

compound 1

oral RET kinase inhibitor

effective in tumor xenograft model

from scaffold hopping & optimization

ACS Medicinal Chemistry Letters

Novartis Genomics Institute

Chemical structure of molecule compound 1 Novartis RET inhibitor
1 min read

14.  The Novartis RET inhibitor, compound 1, demonstrated robust oral in vivo efficacy in RET-driven tumor xenografts at low doses (10 mpk QD). RET inhibitors (selpercatinib and pralsetinib) have recently been approved in RET+ cancers based on significant efficacy in selected patients. Compound 1 was advanced through preclinical studies including rat toxicology but does not appear to have progressed further. It possesses a significantly different structure from the approved RET inhibitors and has interesting bicyclooctane and aniline motifs. The aniline appears to make two critical hydrogen-bonding interactions deep into the active site [based on an analog’s X-ray crystal structure (PDB = 7RUN)] and would be non-trivial to replace.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: